What is Boundless Bio, Inc. Common Stock?
, a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 54.78M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 118,300 shares $54k | 18312,356 shares $736k |
| 3-6months | 0 | 12,975 shares $7k |
| 6-9months | 0 | 0 |
| 9-12months | 0 | 0 |